ABSTRACT
Background Poor glycemic control in diabetic chronic kidney disease (CKD) patients on maintenance hemodialysis is of great challenge, resulting in increased risk of morbidity and mortality. This study aimed to determine the prevalence and determinants of poor glycemic control among diabetic CKD patients on maintenance hemodialysis.
Methodology A cross-sectional study was conducted in 12 dialysis centers located in four regions of Tanzania from March to June 2023. The study population was diabetic CKD patients above 18 years on maintenance hemodialysis for three months or more. A consecutive sampling technique was used for patient recruitment, and a semi-structured questionnaire was used to collect data. The primary outcome was poor glycemic control which was considered when glycated hemoglobin (HbA1c) levels were < 6% or >8%. Statistical Package for Social Sciences (SPSS) version 23 was used for data analysis. Univariate and multivariable regression models were used to evaluate the determinants of poor glycemic control. A p-value <0.05 was considered statistically significant.
Results Out of 233 enrolled patients, the overall prevalence of poor glycemic control was 55.4%, whereby 27.0% had HbA1c <6% and 28.33% had HbA1c >8%. A high risk of HbA1c >8% was observed among patients who were on antidiabetic medication (2.16 (95% CI: 1.06– 4.41) p = 0.035) and those attending dialysis sessions less than 3 times a week (1.59 (95% CI: 1.02– 2.48) p = 0.04). While the predictor of HbA1c <6% was the type of dialyzer used (0.57 (95% CI 0.36 – 0.87) p = 0.020).
Conclusion There is a high prevalence of poor glycemic control among diabetic CKD patients. Patients who were on antidiabetic medication and those who had less than three dialysis sessions had a high risk of HbA1c >8%. In contrast, those dialyzed using glucose-free dialysates had a high risk of HbA1c <6%.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study obtained ethical clearance from Muhimbili University of Health and Allied Sciences (MUHAS) institutional review board (Certificate number: MUHA-REC-02-2023-1533).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Currently data cannot be shared publicly because of we are still analyzing the second manuscript of this work.
